Pfizer Stock (NYSE:PFE)
The application that Pfizer (NYSE:PFE) submitted to the Food and Drug Administration (FDA) of the United States seeking approval for its pentavalent meningococcal vaccination candidate has been accepted for evaluation (MenABCWY). Despite that, Pfizer stock declined in the market.
The pharmaceutical behemoth with headquarters in New York has requested a biologics license application (BLA) for the vaccine MenABCWY, which is intended to protect people aged 10 to 25 against meningococcal illness brought on by the most frequent serogroups.
In October of 2023, it is anticipated that the FDA will decide on the BLA.
The BLA was supported by results from a phase 3 trial showing that MenABCWY was just as effective as Pfizer’s meningococcal disease vaccine Trumenba and GSK’s (NYSE:GSK) Menveo. In doing so, the research achieved both its primary and secondary goals.
Pfizer said on Wednesday that if the vaccine is given the green light, it has the potential to significantly streamline the timetable for being vaccinated against meningococcal disease and deliver the most considerable serogroup coverage of any meningococcal vaccine.
According to the business, MenABCWY combines the components of two different vaccinations into one, making it more effective at protecting against the meningococcal serogroups responsible for the vast majority of cases of invasive meningococcal illness worldwide.
Any sickness brought on by the Neisseria meningitidis bacterium is referred to as a meningococcal disease. According to the Centers for Disease Control and Prevention (CDC), these diseases are often severe and potentially fatal. Among them are infections of the brain and spinal cord (meningitis) lining and blood.
PFE stock decreased 0.37% to $50.94 in premarket trading on December 28.
Featured Image: Pixabay @ mike_ramirez_mx
Author Shariq Khan 
